Radar › Companies › HealthTech · Jiangsu
Radar · HealthTech in Jiangsu

Best HealthTech Companies in Jiangsu, China

The 35 best HealthTech companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.

35companies tracked
$1.4Bdisclosed funding
1unicorns
18have raised
FLIAR INTELLIGENCE · HEALTHTECH × JIANGSU

Our analysis of 50 HealthTech companies

$12.9b in tracked funding; 33% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2021.

50companies analysed
33%cloud-native stacks
2021funding peak (by rounds)
8unicorns
2015median founding year

Ranked: Best HealthTech companies in Jiangsu

#CompanyDisclosed fundingLast roundStageFounderFoundedTech stackPatents & IP focusRecent signals
1Abogen Biosciences 🦄
Developer of mRNA-based therapeutics for cancer and infectious diseases
55Moat top 14%Patents top 17%Innovation top 22%Funding top 27%
All 8 signals ▾
Moattop 14%
Patentstop 17%
Innovationtop 22%
Fundingtop 27%
Talenttop 38%
Marketbottom 44%
Globalbottom 43%
Techbottom 24%
Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents
Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21
rank vs industry peers · Fliar Intelligence Index 55/100
$1.1B52 mo agoSeries CDr InBev
Co-Founder & Co-CEO
2019Animate.cssjQueryHSTS157 patents
Lipid nanoparticle delivery platforms for mRNA and circular RNA therapeutics
—
2Triastek
Provider of 3D printing pharmaceutical technology platform for drug design
69Innovation top 15%Patents top 18%Funding top 31%Moat top 37%
All 8 signals ▾
Innovationtop 15%
Patentstop 18%
Fundingtop 31%
Moattop 37%
Talenttop 38%
Marketbottom 45%
Globalbottom 40%
Newsbottom 22%
Innovation: 196 patents (top 7% of patent-holders) · 125 filings since 2022 vs 68 in 2017-21
Patents: 196 patents matched (strict assignee match) · 125 filings since 2022 vs 68 in 2017-21
rank vs industry peers · Fliar Intelligence Index 69/100
$102M35 mo agoSeries BXiaoling Li
Co-Founder
2015—196 patents
Advanced controlled-release pharmaceutical dosage forms and additive manufacturing technologies
—
3SceneRay
Developer of a portfolio of Neuromodulation devices
$63M55 mo agoSeries D—2011PHPAnimate.cssNginx+3158 patents
Neuromodulation devices and surgical navigation systems for targeted nerve stimulation
1 partnership
412Sigma
AI based medical diagnosis system tools
$32M105 mo agoDeadpooled—2016———
5Baden
B2B e-commerce portal for medical equipment
$25M76 mo agoSeries B—2010Node.jsNginxOpenResty+6——
6Micro Benefits
Employee loyalty solutions provider
$10M126 mo agoSeries C—2010———
7Tuge Medical Tugemedical
Developer of electronic endoscopes and operating room solutions
$7M73 mo agoSeries AWang Yangang
CEO
2018———
851youwe
Online platform for booking housekeeping services
$750K127 mo agoDeadpooledZunjue Jiazhengbao
CEO
2014———
9Medicine Elf Pharmaceutical Retail Pharmacy
Provider of pharmacy management solution
$290K95 mo agoSeedWang Wenfeng
CEO
2016———

Top 12 HealthTech companies in Jiangsu

#1
Series B · Nanjing, Jiangsu · founded 2015 · 46 employees
$102.3Mraised
▾

Provider of 3D printing pharmaceutical technology platform for drug design. The company focuses on the development of 3D bioprinters and Melt Extrusion Deposition (MED) 3D printing technology for dosage form design, and digital pharmaceutical product development.

Fliar Intelligence Index™ 69how this company ranks against its industry peers
Innovation
top 15%
Patents
top 18%
Funding
top 31%
Moat
top 37%
Talent
top 38%
Market
bottom 45%
Innovation: 196 patents (top 7% of patent-holders) · 125 filings since 2022 vs 68 in 2017-21 · Deep-tech classification: Tech Hardware
Patents: 196 patents matched (strict assignee match) · 125 filings since 2022 vs 68 in 2017-21 · Latest publication 2026
Funding: Raised $102M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Series B (Sep 2023)
Audience (LinkedIn): 2k LinkedIn followers — 67.9% of this cohort's audience
Funding rounds
  • Sep 2023Series B$20.4M
  • Jun 2021Series B$51M
  • Dec 2020Series A$15.3M
  • Jun 2018Series A$15.6M
Founders & team
Xiaoling LiCo-FounderSenping ChengCo-Founder & CEO
Investors
Morningside, Volcanics Venture, InnoVision Capital, Matrix Partners China, CPE, Dalton Venture
#2
Series C · Suzhou, Jiangsu · founded 2019
$1.1Braised
▾

Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.

Fliar Intelligence Index™ 55how this company ranks against its industry peers
Moat
top 14%
Patents
top 17%
Innovation
top 22%
Funding
top 27%
Talent
top 38%
Market
bottom 44%
Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents · Unicorn
Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 · Latest publication 2026
Innovation: 157 patents (top 17% of patent-holders) · 154 filings since 2022 vs 3 in 2017-21
Funding rounds
  • May 2022Series C—
  • Nov 2021Series C$300M
  • Aug 2021Series C$720M
  • Apr 2021Series B$91.6M
Founders & team
Dr InBevCo-Founder & Co-CEOYing BoCo-Founder & Co-CEO
Investors
SoftBank Vision Fund, 5Y Capital, Chimera, Mirae Asset, Fortune Ocean, Oriental Fortune Capital
#3
Series D · Suzhou, Jiangsu · founded 2011 · 29 employees
$62.6Mraised
▾

Developer of a portfolio of Neuromodulation devices. The company’s products include a deep brain stimulation system that includes implantable neuro-stimulator, extensions, patient controllers, accessories, leads, clinician programmers, and test neuro-stimulator. It also develops spinal cord stimulation and sacral nerve stimulation systems. Its deep brain stimulators have applications in the treatment of Parkinson's disease, Movement disorders, and Degenerative brain diseases, and its spinal cord and sacral nerve stimulators have applications in neuropathic pain management.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 328 LinkedIn followers — 10.1% of this cohort's audience
Activity: 1 partnerships (incl. Nano Medical Clinic, Uzbekistan) announced in 12 mo
Funding rounds
  • Feb 2022Series D$47.3M
  • Apr 2021Series D$15.4M
Investors
Yanchuang Capital, Deyi Capital, Tahoe Ventures, Sequoia Capital China, Hillhouse Ventures, Cenova
Tech stack
51.LaAnimate.CssJqueryNginxPhpSwiper
#4
Series B · Nanjing, Jiangsu · founded 2010 · 250 employees
$25Mraised
▾

Vedeng is a B2B e-Commerce portal for medical equipment. It claims that it has more than 3000 small dealers located in 31 provinces, more than 280 cities, covering all basic hospitals. Has medical equipment products from all major brands like 3M, Olympus, Haier, etc.

Funding rounds
  • May 2020Series B—
  • May 2018Series A$15.7M
  • Nov 2016Series A$9.4M
  • Jun 2015Series A—
Investors
Sinovation Ventures, Oriental Fortune Capital, Puhua Capital, Marathon Venture Partners, Share Capital, Addor Capital
Tech stack
Baidu Analytics (百度统计)Core-JsNginxNode.JsNuxt.JsOpenresty
#5
Deadpooled · Nanjing, Jiangsu · founded 2016 · 5 employees
$31.7Mraised
▾

12Sigma is Artificial Intelligence based deep-dimensional tool for medical diagnosis. It can be used in medical image analysis and diagnosis, pathology image analysis, and to assist in genomic diagnostics.It aims to help radiologists improve diagnosis accuracy and efficiency, and reduce costs. It has raised $1.5M in Angel round of funding.

Funding rounds
  • Dec 2017Series B$30.2M
  • Apr 2017Seed—
  • Oct 2016Seed$1.5M
Investors
Matrix Partners China, K2VC, Zhen Fund, SBCVC, CD Capital, Delian Capital
#6
Series A · Nanjing, Jiangsu · founded 2018
$7.1Mraised
▾

Developer of electronic endoscopes and operating room solutions. The company has developed an ultra HD endoscopic camera system that is used for hospital endoscopic surgery. It magnifies the in-vivo surgical area and an image is produced of the same for medical observation.

Funding rounds
  • Jul 2020Series A$7.1M
  • 2018Seed—
Founders & team
Wang YangangCEO
Investors
Shanghai Alliance Financial Services, Nanjing Innovation Capital Group, Zhongke Chuangxing, FUHO Capital Management
#7
Series C · Suzhou, Jiangsu · founded 2010 · 51 employees
$10Mraised
▾

Micro Benefits provides employee benefits and loyalty programs that specifically meet the needs of Chinese blue-collar workers and their employers. It uses smartphone applications, SMS messaging platforms, and the web and offers employees low-interest short-term loans, low-cost insurance, affordable educational programs, and discounts for food and other daily necessities.

LinkedIn Pulse recent public activity · Jul 2026
Audience: 712 LinkedIn followers — 22.0% of this cohort's audience
Funding rounds
  • Mar 2016Series C$10M
  • May 2015Series B—
  • 2013Series A—
Investors
Patamar Capital, Xurpas, Peterson Partners, D3 Jubilee Partners, CoinZoom Ventures, Transist
Tech stack
Hubspot Cms HubNginxHubspotJqueryGoogle AnalyticsHsts
#8
Deadpooled · Nanjing, Jiangsu · founded 2014
$750Kraised
▾

51youwe is an online platform where users can book housekeeping services like part-time nannies, nurse, workers to take care of aged people etc. Targets high-end customers for their business. Claims to have an annual customer base of more than 2,00,000 as of Feb 2016. Is currently operational in Nanjing, Suzhou, Shanghai, and Hangzhou as of Feb 2016.

Funding rounds
  • Feb 2016Angel$750K
Founders & team
Zunjue JiazhengbaoCEO
#9
Seed · Zhenjiang, Jiangsu · founded 2016
$290.3Kraised
▾

Medicine Elf Pharmaceutical Retail Pharmacy offers pharmacy management solution. The solution offered by the company provides pharmaceutical invoicing, drug inventory management system, business cashier system, etc.

Funding rounds
  • Sep 2018Seed—
  • Dec 2016Seed$290.3K
Founders & team
Wang WenfengCEO
#10
Series A · Nanjing, Jiangsu · founded 2015 · 100 employees
—raised
▾

AI based disease diagnosis and treatment system. The company has eveloped software that assits with clinical application and management.

Funding rounds
  • Jul 2022Series A—
Founders & team
Zhao JingCo-FounderLi WenyouCo-Founder & CEO
Investors
Orient Securities
#11
Series C · Nanjing, Jiangsu · founded 2014
—raised
▾

Manufacturer of sensors for diagnostics applications. It offers two types of ECG sensors each with the capability of operating in a certain voltage range. Its other offerings include laser modules, integrated ambient light sensor (ALS), proximity sensors (PS), and the infrared LED optical sensor. It also offers chips for the analogue-digital converter and ultra-low power field LCD and LCD driver, WiFi chips, BT chips, and temperature chips. Additionally, it offers services for designing custom transceivers.

Funding rounds
  • Feb 2022Series C—
  • Jan 2021Series B—
  • Oct 2020Series B—
  • May 2019Series B—
Founders & team
Li JipengCEO
Investors
ECC Capital, TCL Equity Investment, CDH, CITIC Capital, Langmafeng Venture Capital, Juntong Capital
#12
Series A · Nanjing, Jiangsu · founded 2019
—raised
▾

Developer of diagnostic devices for cardiac imaging. The company develops intracardiac echocardiography and a 3D echocardiographic mapping system that uses ultrasound imaging to detect and locate the indwelling catheter of the heart. Also, it develops an Ultrasound ablation system.

Funding rounds
  • Dec 2021Series A—
Founders & team
Miao YingyingCo-FounderWang JingCo-FounderZhao DongshengCo-Founder
Investors
TigerYeah Capital, Tao Capital, China-Ticapital.com, Qiming Venture Partners

Funding & investor landscape

$1.4Btotal disclosed funding
9companies funded
18disclosed rounds
0rounds last 90 days
Most active investors
Qiming Venture Partners3 rounds
Hillhouse2 rounds
Jiangsu Qianrong Capital Management2 rounds
Loayal Valley Capital2 rounds
Matrix Partners China2 rounds
Morningside2 rounds
Oriental Fortune Capital2 rounds
Puhua Capital2 rounds
SBCVC2 rounds
TF Capital2 rounds

Notable founders

Xiaoling Li
Co-Founder · Triastek
Senping Cheng
Co-Founder & CEO · Triastek
Dr InBev
Co-Founder & Co-CEO · Abogen Biosciences
Ying Bo
Co-Founder & Co-CEO · Abogen Biosciences
Wang Yangang
CEO · Tuge Medical Tugemedical
Zunjue Jiazhengbao
CEO · 51youwe
Wang Wenfeng
CEO · Medicine Elf Pharmaceutical Retail Pharmacy
Zhao Jing
Co-Founder · Da Jing TCM
Li Wenyou
Co-Founder & CEO · Da Jing TCM
Li Jipeng
CEO · Tianyi Hexin
Miao Yingying
Co-Founder · Tingsn
Wang Jing
Co-Founder · Tingsn
Prism market signals · China · country-scoped Prism corpus, 457,648 docs

Market landscape — 10 sub-themes by coverage

Share of HealthTech coverage by sub-theme.

Regulatory-risk over time rising

Funding & growth over time

funding rising · growth rising

RESEARCH IN JIANGSU · Health & Bio

How research on Digital Health in Jiangsu is moving

A read on the academic research around Digital Health in Jiangsu — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 43 papers.

43 papers · stance +0.25 · 18% breakthrough · 35% concern
breakthrough · advancement · concern
top institutions
  • Jiangsu University16
  • Jiangsu Province Hospital7
  • Northern Jiangsu People\'s Hospital4
  • Jiangsu Provincial Center for Disease Control and Prevention3
  • Jiangsu Normal University2
leading researchers
Jonathan Aseye Nutakor · Lülin Zhou · Xinglong Xu · Yupeng Cui · Abid Hussain · Jian Jia
prism intelligence · tone & topics
77% positive · 16% critical tone
HealthcareSocietyBusinessPublic HealthEducationGovernment
▲ Breakthroughs6 · 14%
▲ 0%→15% share
0 median citations100% since 2021mostly methods-led
Breakthroughs are rising (0%→15% of field), led by Biosensor.
rising sub-themes (early→recent)
  • Biosensor1
  • Therapeutic drug monitoring1
  • Plasma1
  • Biochip1
  • Remote patient monitoring1
Landmark Information literacy and intention to adopt e-pharmacy: a study based on trust and the theory of reasoned action · 10 cites
◆ Advancements16 · 37%
▲ 0%→39% share
1 median citations100% since 2021mostly empirical
Advancements are rising (0%→39% of field), led by Mediation.
rising sub-themes (early→recent)
  • Mediation4
  • Health informatics3
  • Wearable computer2
  • Atrial fibrillation2
  • Public health2
Newly emergingMediation 0→4 · Health informatics 0→3
Landmark The mediating effects of perceived usefulness and perceived ease of use on nurses’ intentions to adopt advanced technolo · 50 cites
▼ Concerns12 · 28%
▲ 0%→27% share
1 median citations92% since 2021mostly position pieces
Concerns are rising (0%→27% of field), led by Health informatics.
rising sub-themes (early→recent)
  • Health informatics1→3
Newly emergingHealth administration 0→3 · Health care 0→3 · Psychological intervention 0→3
Landmark Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study · 166 cites

Common questions

How many HealthTech companies are there in Jiangsu, China?
Radar tracks 35 indexable HealthTech companies headquartered in Jiangsu, China that meet our profile-completeness bar.
What is the total funding raised by HealthTech companies in Jiangsu, China?
The HealthTech companies in Jiangsu, China on this list have raised a combined $1.4B in disclosed equity funding across 9 funded companies.
Which is the highest-funded HealthTech company in Jiangsu, China?
Abogen Biosciences is the highest-funded HealthTech company in Jiangsu, China, with $1.1B in disclosed equity funding.
How many HealthTech companies in Jiangsu, China are funded?
9 of the 35 HealthTech companies in Jiangsu, China on this list have disclosed at least one equity funding round.
How many HealthTech unicorns are there in Jiangsu, China?
1 HealthTech company in Jiangsu, China on this list is valued at $1B or more.
Who are the top investors in Jiangsu, China HealthTech companies?
The most active investors in Jiangsu, China HealthTech companies on this list include Qiming Venture Partners, Hillhouse, Jiangsu Qianrong Capital Management, Loayal Valley Capital, Matrix Partners China.
Rohit KhannaTrends & Stories

Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.

Coming soon